Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nimbus Saturn
Cambridge/Boston, Massachusetts, United Statesnimbustx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Nimbus has demonstrated strong early-stage clinical results with its WRN inhibitor NDI‑219216 in advanced solid tumors. Its TYK2 inhibitor showed positive Phase IIb data in plaque psoriasis before being acquired by Takeda. The company’s computational approach has enabled the rapid advancement of highly selective small molecules against challenging targets.
- Therapeutic areas
- OncologyImmunologyCardiovascularMetabolic Disorders
- Modalities
- Small moleculeProteolysis-targeting chimera therapy (PROTAC)
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Nimbus Saturn.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimbus Saturn.